Brexit: first aid for pharma, with legal expert Elisabethann Wright

21 June 2016

In our weekly expert view piece, Elisabethann Wright, partner at international law firm Hogan Lovells, outlines some of the potential risks if British voters opt to exit the European Union (EU).

The life sciences industry, including the pharmaceutical industry, is one of the UK's leading manufacturing sectors. It employs in the region of 90,000 people with exports of medicinal products alone valued at more than £21 billion ($30.9 billion) per year.

The other 27 EU member states represent an important market for UK medicinal products, exported to their territories on the basis of a marketing authorization held by a UK holder.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK